- Home
- ETON vs BOLD Comparison
ETON vs BOLD Comparison
Compare ETON & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- BOLD
- Stock Information
- Founded
- ETON 2017
- BOLD 2018
- Country
- ETON United States
- BOLD United States
- Employees
- ETON N/A
- BOLD N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- ETON Health Care
- BOLD
- Exchange
- ETON Nasdaq
- BOLD Nasdaq
- Market Cap
- ETON 388.3M
- BOLD 24.4M
- IPO Year
- ETON 2018
- BOLD 2024
- Fundamental
- Price
- ETON $18.46
- BOLD $1.14
- Analyst Decision
- ETON Strong Buy
- BOLD Buy
- Analyst Count
- ETON 3
- BOLD 4
- Target Price
- ETON $29.67
- BOLD $4.00
- AVG Volume (30 Days)
- ETON 205.9K
- BOLD 66.0K
- Earning Date
- ETON 11-11-2025
- BOLD 11-06-2025
- Dividend Yield
- ETON N/A
- BOLD N/A
- EPS Growth
- ETON N/A
- BOLD N/A
- EPS
- ETON N/A
- BOLD N/A
- Revenue
- ETON $58,181,000.00
- BOLD N/A
- Revenue This Year
- ETON $105.25
- BOLD N/A
- Revenue Next Year
- ETON $40.84
- BOLD N/A
- P/E Ratio
- ETON N/A
- BOLD N/A
- Revenue Growth
- ETON 85.40
- BOLD N/A
- 52 Week Low
- ETON $5.35
- BOLD $1.00
- 52 Week High
- ETON $21.48
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- ETON 67.44
- BOLD 47.21
- Support Level
- ETON $17.24
- BOLD $1.13
- Resistance Level
- ETON $18.52
- BOLD $1.19
- Average True Range (ATR)
- ETON 0.70
- BOLD 0.04
- MACD
- ETON -0.02
- BOLD 0.00
- Stochastic Oscillator
- ETON 93.16
- BOLD 44.44
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.